The global respiratory inhaler devices market is on the cusp of significant transformation over the next decade, driven by a rising incidence of respiratory diseases, technological advancements, and ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...

Italian biopharma Chiesi Group has announced a major investment in Nerviano, near Milan, with the building of a new facility ...

And while other options exist like dry-powder inhalers and soft mist inhalers, MDIs are still the best option for many patients for a variety of reasons, according to AstraZeneca.

In this video, Andrea Pappalardo, MD, discusses the developments in targeted therapies and technologies for pediatric asthma.

Background: The proliferation of inhaler devices has resulted in a confusing number of choices for clinicians who are selecting a delivery device for aerosol therapy. There are advantages and ...

“It’s important to include a one- to two-day day supply of medications taken for chronic conditions, like diabetes or high ...

Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced that the U.S. Food and Drug ...

Objective: To review the basis for the estimated comparative daily dosages of inhaled corticosteroids for children and adults that are presented in the National Heart, Lung, and Blood Institute's ...